Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 426 - 450 of 814 in total

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used to prevent invasive meningococcal disease, which is caused by bacteria Neisseria meningitidis entering the bloodstream and invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and pneumonia. Several serogroups of N....
Approved
Matched Name: … Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine …
Matched Description: … Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is used ... meningococcal disease, which is caused by bacteria _Neisseria meningitidis_ entering the bloodstream and ... invading the blood-brain barrier to cause a variety of infections such as septicemia, meningitis, and …

Fluoxymesterone

An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
Approved
Illicit
Matched Description: … anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Cysteamine

Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys. Several preparations of cysteamine exist...
Approved
Investigational
Matched Description: … [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily ... in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and ... preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and …
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism …

Dexamethasone acetate

Commonly known as decadron, dexamethasone acetate is a glucocorticosteroid previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and other conditions.[T797,L10695,L14348] Developed in 1957, dexamethasone is structurally similar to other corticosteroids such as hydrocortisone and prednisolone. Dexamethasone acetate has largely been replaced by dexamethasone phosphate and...
Approved
Investigational
Vet approved
Matched Description: … In a June 16 2020 press release highlighting early results of a clinical trial, Randomized Evaluation ... one-third in patients on oxygen therapy and mechanical ventilation, respectively. ... previously marketed in the USA for the treatment of inflammatory respiratory, allergic, autoimmune, and …

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the...
Approved
Investigational
Matched Description: … approved on March 2nd, 2020, for the treatment of multiple myeloma. ... L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and ... dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Fenfluramine

Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712,...
Approved
Illicit
Investigational
Withdrawn
Matched Description: … initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020 ... It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity ... Concomitantly with these seizures, patients typically display delayed development and neurocognitive …
Matched Categories: … Alimentary Tract and Metabolism …

Inebilizumab

Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … , A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020 ... Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Lurbinectedin

Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate...
Approved
Investigational
Matched Description: … [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin ... including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,[A214322] and ... [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Flortaucipir F-18

Flortaucipir F-18, also known as 18F-T807 and 18F-AV-1451, is a small indole molecule synthesized with a radioactive fluorine isotope. It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. After crossing the blood-brain barrier, flortaucipir F-18 binds to aggregated tau protein,...
Approved
Investigational
Matched Description: … It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID ... MAO-B, as well as to regions containing high levels of melanin, neuromelanin, and iron. ... ™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain. …

Casirivimab

Casirivimab is a monoclonal antibody combined with Imdevimab in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. This drug is a combination of antibodies derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to...
Approved
Experimental
Matched Description: … [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild ... [L39130,L39135] Full safety and efficacy data are not yet available, and further evaluation of this ... to moderate COVID-19 in patients aged 12 years and older. …
Matched Mixtures name: … Casirivimab and Imdevimab ... Casirivimab and Imdevimab …
Matched Categories: … casirivimab and imdevimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Pyrethrum extract

Pyrethrum is the crude extract form obtained from flowers of the plant Chrysanthemum cinerariifolium. Pyrethrin refers to a more refined extract of pyrethrum. While pyrethrum extract is composed of 6 esters, both organic compounds mediate insecticidal activities. Pyrethrum-containing mixtures are used as a common insecticide to control specific pest species....
Approved
Matched Synonyms: … Pyrethrins and pyrethroids …
Matched Description: … Pyrethrum extract is also used used to treat head, body, and pubic lice infections. ... The active compound is absorbed by the lice and destroys them by acting on their nervous systems but …
Matched Mixtures name: … Medi and Lice Lice Killing ... Lice-Nil Lice and Eggs Killer ... Weeks and Leo Complete Lice Treatment …

Factor IX Complex (Human)

Factor IX Complex is a sterile, lyophilized concentrate composed of a number of Vitamin K-dependent clotting factors found in functioning human plasma. Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels of...
Approved
Investigational
Matched Synonyms: … Coagulation factor IX, II, VII and X in combination …
Matched Description: … Coagulation factors are purified from pooled human plasma and subsequently sterilized and treated. ... For example, Kcentra (FDA) also contains the antithrombotic proteins C and S, while Bebulin VH (FDA) ... include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …

Siponimod

Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Description: … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 ... , disrupting communication between the brain and other parts of the body. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Fostemsavir

Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in...
Approved
Investigational
Matched Description: … [A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 ... of gp120 as a potential target of interest in the treatment of HIV-1 infection is relatively recent, and ... [L14867,L14917] Targeting gp120 subunits is a new and novel therapeutic approach to HIV-1 infection, …

Naxitamab

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved
Matched Description: … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for ... [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and ... within neuroblastomas (and other neuroectodermal tumors),[A224609] and is rarely subject to antigen …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Mefloquine

Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and...
Approved
Investigational
Matched Description: … The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality ... Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling ... It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. …
Matched Categories: … artesunate and mefloquine ... Antiparasitic Products, Insecticides and Repellents …

Nirmatrelvir

Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. Without the activity of the SARS-CoV-2 3CLPRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.[A234224,A234229,A234234]...
Approved
Investigational
Matched Description: … [A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV ... [L33354] 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. ... in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and …
Matched Categories: … nirmatrelvir and ritonavir ... Amino Acids, Peptides, and Proteins …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Description: … [A193533] Selumetinib was approved by the FDA on April 10, 2020. ... [A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading ... Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Abametapir

Abametapir is a novel pediculicidal metalloproteinase inhibitor used to treat infestations of head lice. The life cycle of head lice (Pediculus capitis) is approximately 30 days, seven to twelve of which are spent as eggs laid on hair shafts near the scalp. Topical pediculicides generally lack adequate ovicidal activity, including...
Approved
Investigational
Matched Description: … Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020 ... agents like permethrin and [pyrethrins]/[piperonyl butoxide] may be significant in some areas. ... The necessity for follow-up treatment may lead to challenges with patient adherence, and resistance to …
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …

Vadadustat

One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in erythropoietin (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous...
Approved
Investigational
Matched Description: … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved ... [A244165] A relatively new and alternative treatment option for patients with anemia associated with ... [A244165] Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Capmatinib

Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
Approved
Investigational
Matched Description: … approval by the FDA on May 6, 2020,[L13380] for the treatment of NSCLC in patients whose tumors have ... such as STAT3, PI3K/ATK, and RAS/MAPK. ... [A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tafasitamab

Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity relative to non-engineered anti-CD19...
Approved
Investigational
Matched Description: … the FDA,[A191829] tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020, for ... results in the lysis of B-cells (both healthy and malignant). ... [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Bamlanivimab

Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to...
Approved
Investigational
Matched Description: … interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020 ... 19 in adults and children. ... Infectious Diseases (NIAID), and subsequently further developed it in collaboration with Eli Lilly and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Pemigatinib

Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide...
Approved
Investigational
Matched Description: … This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% ... [A193716] In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally ... physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 426 - 450 of 814 in total